Virginia Commonwealth University

VCU Scholars Compass
Psychiatry Publications

Dept. of Psychiatry

2015

QTc Prolongation in Veterans With Heroin
Dependence on Methadone Maintenance
Treatment
Sameer Hassamal
Virginia Commonwealth University, shassamal@mcvh-vcu.edu

Antony Fernandez
Virginia Commonwealth University, McGuire Veterans Affairs Medical Center

Hossein Moradi Rekabdarkolaee
Virginia Commonwealth University

Ananda Pandurangi
Virginia Commonwealth University, apandura@vcu.edu

Follow this and additional works at: http://scholarscompass.vcu.edu/psych_pubs
Part of the Psychiatry and Psychology Commons
Copyright © 2015, Zahedan University of Medical Sciences. This is an open-access article distributed under the terms of
the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/
by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work
is properly cited.

Downloaded from
http://scholarscompass.vcu.edu/psych_pubs/50

This Article is brought to you for free and open access by the Dept. of Psychiatry at VCU Scholars Compass. It has been accepted for inclusion in
Psychiatry Publications by an authorized administrator of VCU Scholars Compass. For more information, please contact libcompass@vcu.edu.

Int J High Risk Behav Addict. 2015 June; 4(2): e23819.

DOI: 10.5812/ijhrba.4(2)2015.23819
Research Article

Published online 2015 June 20.

QTc Prolongation in Veterans With Heroin Dependence on Methadone
Maintenance Treatment
1,*

Sameer Hassamal ; Antony Fernandez
1
Pandurangi

1,2

3

; Hossein Moradi Rekabdarkolaee ; Ananda

1Department of Psychiatry, Virginia Commonwealth University, Virginia, USA
2McGuire Veterans Affairs Medical Center, Richmond, Virginia, USA
3Department of Statistical Sciences, Virginia Commonwealth University, Virginia, USA

*Corresponding author: Sameer Hassamal, Department of Psychiatry, Virginia Commonwealth University, Virginia, USA. Tel: +1-6263991005, E-mail: shassamal@mcvh-vcu.edu

Received: September 23, 2014; Revised: October 26, 2014; Accepted: December 2, 2014

Background: QTc prolongation and Torsade de Ppointes have been reported in patients on methadone maintenance.
Objectives: In this study, QTc was compared before and after the veteran (n = 49) was on a stable dosage of methadone for 8.72 ± 4.50 years
to treat heroin dependence. Risk factors were correlated with the QTc once the veteran was on a stable dose of methadone. Differences in
the clinical risk factors in subgroups of veterans with below and above mean QTc change was compared.
Patients and Methods: ECG data was obtained from a 12-lead electrocardiogram (pre-methadone and on methadone) on 49 veterans.
Data and risk factors were retrospectively collected from the medical records.
Results: The mean QTc at baseline (pre-methadone) was 426 ± 34 msec and after being on methadone for an average of 8.72 ± 4.50 years
was significantly higher at 450 ± 35 msec. No significant relationships were found between QTc prolongation and risk factors except for
calcium. The methadone dosage was significantly higher in veterans with a QTc change above the mean change of ≥ 24 msec (88.48 ± 27.20
mg v.s 68.96 ± 19.84 mg). None of the veterans experienced cardiac arrhythmias.
Conclusions: The low complexity of medical co-morbidities may explain the lack of a significant correlation between any risk factor with
the QTc except calcium and methadone dosage. The absence of TdP may be explained by the low prevalence of QTc values > 500 msec as
well as the retrospective design of the study. During long-term methadone treatment, there was a slight increase in the QTc interval but we
did not find evidence of increased cardiac toxicity as a reason for treatment termination.
Keywords: Opiate Substitution Treatment; Heroin Dependence; Arrhythmia; Torsades de Pointes

1. Background
Since the advent of methadone maintenance programs,
there has been an overall increase in the life expectancy
of heroin users (1). Methadone, a mu-receptor agonist, is a
synthetic opiate that is commonly used in the treatment
of opiate dependence (1). However, there are concerns
regarding the disturbance of cardiac rhythm among individuals receiving methadone maintenance treatment,
e.g., Torsade de Ppointes (TdP) secondary to rate-corrected
QT interval prolongation (QTc) (1-3). There are many proposed thresholds for determining the value at which the
QTc is considered prolonged; however, international regulatory guidelines suggest a sex-independent categorical
threshold for QTc of 450 msec as a risk factor for TdP (1).
However, the low prevalence of TdP precludes using QTc
prolongation alone to determine the risk of developing
this condition (4). Arrhythmias are more likely to occur if
drug-induced QTc prolongation co-occurs with other risk
factors for QT prolongation, such as the presence of congenital long QT syndromes, heart failure, bradycardia,
electrolyte imbalances (hypokalemia, hypomagnesae-

mia, hypocalcaemia, hypophosphatemia), female sex, advanced age, hepatic impairment, slow metabolization of
methadone, concomitant use of a QTc-prolonging drug,
cytochrome P-450 inhibitors such as selective serotonin
reuptake inhibitors, antiretroviral medications and antipsychotic medications (5, 6). Justo and colleagues found
that the most prevalent risk factors for QTc prolongation
were high-dose methadone (mean methadone dose was
231 ± 201 mg/day), drugs such as fluconazole and fluvoxamine that increase serum methadone levels, HIV infection, hypokalemia, female sex, liver cirrhosis, and cardiovascular disease (7).

2. Objectives
The aim of this study was to examine changes in the QTc
duration before and after being on stable methadone
treatment in veterans with heroin dependence and to assess QTc with risk factors such as methadone dosage, age,
hypokalemia, hypocalcaemia, hypomagnesaemia, hypo-
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phosphatemia, systolic congestive heart failure, hepatic
cirrhosis, antidepressant medication use, antipsychotic
medication use, other QTc prolonging medications and
gender, both independently and as a group, in a veteran
patient population on a stable dose of methadone for
opiate dependence (5-8). The relationship between the
above risk factors as a group and the change in the mean
QTc post-methadone was also analyzed. Differences in
the clinical risk factors for veterans with a QTc change ≥
24 msec were compared to those with a QTc change < 24
msec after being on methadone for an average of 8.72 ±
4.50 years.

3. Patiants and Methods
3.1. Participants
The McGuire VAMC Opioid Agonist Treatment program
provides integrated services to veterans with opiate
dependence. At the time of the study, 47 male and 2 female veterans were receiving methadone maintenance
treatment. All of the 49 veterans meet DSM-IV criteria for
heroin dependence (9). In this clinic, methadone liquid is
administered at different dosages based on the veteran’s
needs. At every methadone visit, an observed urine drug
screen is performed. Initially, the veterans come into the
methadone clinic daily for at least 90 days to pick up their
daily dose of methadone. For every 90 negative urine
drug screens, the veteran will get one extra take home
dose of methadone. On average, veterans receive a 14day supply of methadone at each visit, which translates
to 1260 negative consecutive drug screens. For a positive
urine drug screen, the veteran will lose methadone take
home privileges. 3 positive urine drug screens usually result in termination from the clinic. Comprehensive metabolic profiles and electrocardiograms were collected on
admission to the program and yearly thereafter. Veterans
with severe cardiopulmonary and liver disease were excluded from methadone maintenance treatment.

3.2. Procedures
The McGuire Veterans Hospital Institutional Review
Board (IRB) approved our retrospective study. The study
protocol conforms to the ethical guidelines of the 1975
Declaration of Helsinki. Opiate dependence was defined
using the DSM-IV criteria (9). All veterans enrolled in the
methadone maintenance treatment program undergo
routine laboratory analyses. From retrospective chart review, the most recent clinical data available after being on
methadone was collected on all 49 veterans enrolled in
the methadone maintenance program at the time of the
study. Clinical data included 12-lead electrocardiograms
and risk factors for QTc prolongation such hypokalemia,
hypocalcaemia, hypomagnesaemia, hypophosphatemia,
methadone dose, age, gender, systolic congestive heart
failure, hepatic cirrhosis, antidepressant medication use,
2

antipsychotic medication use, and the use of other QTc
prolonging medications such as levofloxacin, atazanavir/ritonavir, efavirenz, diltiazem, ciprofloxacin, trimethoprim-sulfamethoxazole, azithromycin and vardenafil.
Additional clinical data collected included full time employment status, race, substance use disorder comorbidity, psychiatric disorder comorbidity and body mass index. Electrocardiogram data prior to starting methadone
was also collected on all 49 veterans.

3.3. Clinical Variables
The QTc prior to initiating methadone treatment and
the most up-to-date risk factors for QTc prolongation
were correlated with the most recent QTc once the veteran had been on a stable dose of methadone. The QT
interval was corrected for the heart rate using Bazett’s
formula, QTc = QT√RR (10). Hypokalemia was defined
as a potassium level of less than 3.5 mEq/L; hypocalcaemia was defined as a calcium level of less than 8.5 mg/
dL; hypomagnesaemia was defined as a magnesium
level of less than 1.5 mg/dL; and hypophosphatemia
was defined as a phosphorous level of less than 2.5 mg/
dL. Systolic congestive heart failure was defined as having an ejection fraction less than 45%. Hepatic cirrhosis
was defined as having ultrasound imaging or a liver
biopsy showing hepatic fibrosis as well as documentation confirming the diagnosis of cirrhosis. Other QTc
prolonging medications included levofloxacin, atazanavir/ritonavir, efavirenz, diltiazem, ciprofloxacin,
trimethoprim-sulfamethoxazole, azithromycin and
vardenafil. All statistical analyses were calculated using IBM SPSS software (11). QTc was correlated with risk
factors as a dichotomous variable at 450 msec and as a
continuous variable. The P-Value was set at ≤ 0.05. Continuous variables (methadone dosage and age) were independently correlated with a dichotomized QTc using
a Point bi-serial correlation and a continuous QTc using
a Pearson correlation. Ordinal variables (hypophosphatemia, hypocalcaemia, hypokalemia, hypomagnesaemia, systolic congestive heart failure, liver cirrhosis)
were independently correlated with a dichotomous
and continuous QTc through Kendall’s tau correlations.
Dichotomous variables (gender, antidepressant use,
antipsychotic use, other QTc prolonging medications)
were correlated with a dichotomized QTc based on the
Phi Coefficient and the continuous QTc based on a Pearson’s correlation. Multivariate ANOVA was performed to
correlate the clinical risk factors (phosphate, calcium,
potassium, magnesium, systolic heart disease, hepatic
cirrhosis, methadone dose, age, gender, use of antidepressant, use of antipsychotic medication, use of other
QTc prolonging medications) as a group with the QTc
as well as with the mean change in the QTc after 8.72 ±
4.50 years of Methadone Maintenance Treatment. A chi
square and independent t-test was performed to analyze
the difference in the clinical risk factors (phosphate, calInt J High Risk Behav Addict. 2015;4(2):e23819
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cium, potassium, magnesium, systolic heart disease,
hepatic cirrhosis, gender, use of antidepressant, use of
antipsychotic medication, use of other QTc prolonging
medications, methadone dose, age) between those veterans with a QTc change ≥ 24 msec and those with a QTc
change < 24 msec after being on methadone for 8.72 ±
4.50 years. A change in the QTc of ≥ 24 msec was used to
separate the veterans into two separate groups because
the mean change in the QTc after being on a stable dose
of methadone for all veterans was 24 msec.

4. Results

All the 49 veterans were receiving methadone maintenance for heroin dependence (Table 1). The mean QTc (±
SD) prior to initiating methadone treatment was 426 ± 34
msec. The most recent EKG had been obtained after having been on a stable dose methadone for an average (±
SD) of 8.72 ± 4.50 years. The mean QTc (± SD) after being on
methadone for 8.72 ± 4.50 years was 450 ± 35 msec.
Table 1. Sociodemographic Characteristics of the Sample (n = 49) a
Variable
Age, y

Body Mass Index, Kg/m2
Gender
Male

Frequency

56.96 ± 6.48
29.63 ± 6.61
47 (96)

Female

2 (4)

Caucasian

11 (22)

African American

38 (78)

Race/Ethnicity

Full Time Employment

Substance Use Disorder Comorbidity

17 (35)

None

5 (10)

Alcohol

2 (4)

Cocaine

14 (29)

Nicotine

8 (16)

Marijuana

2 (4)

Multiple

18 (37)

Post-Traumatic Stress Disorder

18 (37)

Psychiatric Disorder Comorbidity

Major Depressive Disorder

3 (6)

Depressive Disorder Not Otherwise
Specified

7 (14)

Attention Deficit Hyperactivity Disorder

1 (2)

Substance-Induced Mood Disorder

3 (6)

Multiple Diagnosis (≥ 2)

4 (8)

a Data are presented as No. (%) or Mean ± SD.
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4.1. Overall Effect of Methadone on the QTc
A paired t-test showed that the mean increase in the QTc
(24 msec) after being on methadone treatment for an average of 8.72 ± 4.50 years was statistically significant (t =
-4.62, df = 46, P < 0.01).

4.2. Prevalence of Risk Factors for QTc Prolongation
and TdP

Methadone Dose: The mean dose of methadone (± SD)
prescribed was 78.20 ± 25.30 mg/day. QTc prolongation:
On admission to the methadone maintenance treatment program, 40 veterans (82 %) displayed a QTc less
than or equal to 450 msec, while 9 (18%) displayed a QTc
greater than 450 msec. 4 veterans had a QTc between 450
to 475 msec, 3 veterans had a QTc between 475 msec and
500 msec, 1 veteran had a QTc between 500 msec and
525 msec, 1 veteran had a QTc between 525 msec and 550
msec. The average heart rate (± SD) was 72.00 ± 11.81 bpm.
After being on methadone for an average of 8.72 ± 4.50
years, 26 (53%) veterans displayed a QTc of less than or
equal to 450 msec, while 23 (47%) exhibited a QTc greater
than 450 msec. 19 veterans had a QTc between 450 msec
and 475 msec; 2 veterans had a QTc between 475 msec and
500 msec; 1 veteran had a QTc between 500 msec and 525
msec; 3 veterans had a QTc between 525 msec and 550
msec. The average heart rate (± SD) was 70.00 ± 12.89 bpm.
TdP: Despite the fact that 47% of the participants presented a QTc greater than 450 msec post methadone,
none of the participants experienced any arrhythmias.
Psychotropic Medications: 24 (49%) were on an antidepressant medication; and 4 (8%) were on an antipsychotic
medication.
Electrolytes: 6 (12%) veterans were hypokalemic, 11
(22.45%) had hypocalcaemia while 10 (20%) had hypomagnesaemia, and 1 (2%) had hypophosphatemia. Co-morbid
physical disorders: 13 (26.53%) had cirrhosis, 2 (4.08%) had
systolic congestive heart failure.

4.3. Effect of Risk Factors on the QTc After Initiating
Methadone
Point-biserial correlations revealed no significant association between the dichotomized QTc and methadone
dosage (r = 0.19, P = 0.19) or age (r = 0.17, P = 0.24). Pearson’s correlation revealed no significant correlation
between the continuous QTc and methadone dosage (r
= 0.18, P = 0.22) or age (r = 0.17, P = 0.24). Kendall’s Tau
correlations did not indicate any significant association
between dichotomized QTc and potassium (τ = -0.18, P
= 0.20), magnesium (τ = -0.11, P = 0.48), phosphate (τ =
-0.15, P = 0.33), systolic heart failure (τ = 0.225, P = 0.06)
or cirrhosis (τ = -0.20, P = 0.09). However, Kendall’s
Tau correlations did indicate a significant association
between dichotomized QTc and calcium (τ = -0.35, P =
0.02). Similarly, Kendall’s Tau correlations did not show
any significant correlations between continuous
3
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Table 2. Case Report Risk Factors for QTc Interval Prolongation and Torsade de Pointes (TdP) in Descending Order of the Change in
the QTc on a Stable Dose of Methadone
Case #
#38
#21

#23
#3

#32
#41
#31
#9

#28
#7

#19

#48

#40
#45
#36

#44
#12

#20
#43
#2

#27

#30
#17

#29

#46
#35
#33
#11
#5

#14

#26
#18
#13
#6

#37

#22
#42
#25
#8

#4

#34

#49
#39
#16

#47
#15

#24
#10
#1

4

Current risk Factors Other Than
Methadone

Pre methadone
QTc, msec

On a stable dose of
methadone QTc, msec

398

520

453

549

75

401

476

hypo-K+, hypo-ca++, trazodone

60

412

sertraline, trazodone

55

hypo-mg++

Change in
QTc, msec
122

none

108

430

venlafaxine

79

377

quetiapine
none

bradycardia, citalopram
trazodone

paroxetine

hypo-ca++, azithromycin
bradycardia, diltiazem

96

68

387

58

390

55

402

51

400

41

433

51

403

538

65

458

60

55

70

50

434

36

394

430

none

35

28

424

452

hepatic cirrhosis, hypo-Mg++, trazodone

28

474

110
80
85

471

175

422

450

65

394

422

100

420

100

hypo-Ca++

24

400

none

23

382

396

55

56

64

399

418

59

45

risperidone, levofloxacin, trazodone

hypo-po43-, hypo-ca++, hepatic cirrhosis,
azithromycin, trazodone

55

60

451

female, hypo-K+, bradycardia, venlafaxine

24

90

41

52

100

450

hepatic cirrhosis

85

61

457

452

410

28

61

448

40

hepatic cirrhosis

120

120

472

hepatic cirrhosis, hypo-mg++, azithromycin,
ciprofloxacin, trimethoprim sulfamethoxazole,
trazadone

28

56

455

45

hepatic cirrhosis

85

90

100

401

436

Age, y

456

none

hypo-mg++, hypo-ca++, amitryptiline

Methadone daily
dose, mg

446
424

405

70

59
59
53
51

55
61

64

85

60

80

59

95

39

61

62

21

439

460

50

hepatic cirrhosis, hypo-mg++, hypo-ca++,
sertraline

20

431

451

100

62

hypo-ca++, systolic heart failure

levofloxacin, hypo-ca++

19

479

55

63

hypo-k+, hypo-mg++, bradycardia, sertraline

15

14

431

bradycardia

12

hypo-ca++, amitriptyline
atazanavir, ritonavir

14

466

413

427

398

8

424

4

470

hepatic cirrhosis, systolic heart failure, hypok+, hypo-mg++, hypo-ca++, trazodone

0

536

female

0

hepatic cirrhosis, quetiapine, sertraline

6

bradycardia

1

hypo-k+

498

451

445
410

432

536

70

60
90

459

hepatic cirrhosis, mirtazapine

0

434

434

hypo-Mg++
vardenifil
none

efavrienz, trazodone

hepatic cirrhosis, hypo-Mg++, trazodone
mirtazapine, bradycardia
none

hypo-mg++, hypo-ca+, quetiapine,
nortriptyline

0

428
416

439

64

50

55

416

409

396

-22

484

-56

499

-64

51

80

-13

-29

57

428

403

-15

58

54

50

403
445

75

56

55

0

-3

59

399

439

61

63

59

398

474

75

70

60

100

459

sertraline, hepatic cirrhosis

55

442

0

0

80

436

hypo-k+, trazodone

bradycardia

70

53

55

45

54
61

442

60

60

401

100

57

438

409

30

55

519

455

40

62

416

462
443

90
70

90

55
57
37
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QTc and potassium (τ = 0.11, P = 0.35), magnesium (τ
= 0.06, P = 0.62), phosphate (τ = -0.14, P = 0.25), systolic
heart failure (τ = 0.22, P = 0.07) or cirrhosis (τ = -0.08,
P = 0.52). However, Kendall’s Tau correlations did show a
significant correlation between the continuous QTc and
calcium (τ = -0.25, P = 0.05). The phi coefficient did not
show any significant association between the dichotomized QTc and gender (φ = -0.19, P = 0.17), antidepressant use (φ = 0.14, P = 0.32), antipsychotic use (φ = 0.17,
P = 0.24), and other QTc prolonging medications (φ =
0.09, P = 0.53). The Pearson’s correlation did not show
any significant correlation between the continuous QTc
and gender (r = -0.09, P = 0.53), antidepressant use (r =
-0.06, P = 0.69), antipsychotic use (r = 0.26, P = 0.07) and
other QTc prolonging medications (r = -0.02, P = 0.87).

4.4. Effect of the Risk Factors as a Group on the QTc
After Initiating Methadone
Multivariate ANOVA did not show a significant correlation between the risk factors as a group (methadone
dosage, age, hypokalemia, hypocalcaemia, hypomagnesaemia, hypophosphatemia, systolic congestive heart
failure, hepatic cirrhosis, antidepressant medication
use, antipsychotic medication use, other QTc prolonging
medications, and gender) and the continuous QTc (F =
1.18, df = 12, P = 0.34).

4.5. Effect of the Risk Factors as a Group on the
Change in the QTc After Initiating Methadone
Multivariate ANOVA did not show a significant correlation between the risk factors as a group (methadone
dosage, age, hypokalemia, hypocalcaemia, hypomagnesaemia, hypophosphatemia, systolic congestive heart
failure, hepatic cirrhosis, antidepressant medication
use, antipsychotic medication use, other QTc prolonging
medications, gender) and the mean change in the QTc (F
= 1.78, df = 12, P = 0.10).

4.6. Difference in the Clinical Risk Factors Between
Veterans With a Change of QTc ≥ 24 Msec and
Those With a QTc < 24 Msec

A chi-square did not show any significant differences in
antidepressant use (χ2 = 0.18, df = 1, P = 0.67), antipsychotic use (χ2 = 0.02, df = 1, P = 0.90), other QTc prolonging medication (χ2 = 0.05, df = 1, P = 0.84), gender (χ2 =
0.01, df = 1, P = 0.93), hypocalcaemia (χ2 = 0.91, df = 1, P =
0.34), hypomagnesaemia (χ2 = 0.28, df = 1, P = 0.60), hypophosphatemia (χ2 = 1.18, df = 1, P = 0.28), hypokalemia
(χ2 = 1.20, df = 2, P = 0.55) systolic congestive heart failure
(χ2 = 1.84, df = 1 P = 0.18) and hepatic cirrhosis (χ2 = 0.50,
df = 1, P = 0.48) between the 2 groups of veterans. An independent t-test did not show a significant difference in
age between the 2 groups of veterans (t = -0.17, df = 47, P =
0.86). The mean dose of methadone prescribed for veterans (88.48 ± 27.20 mg) with a change in QTc ≥ 24 msec was
Int J High Risk Behav Addict. 2015;4(2):e23819

significantly higher than the mean dose of methadone
(68.96 ± 19.84 mg) prescribed for veterans with a change
in QTc < 24 msec (t = 2.82, df = 45 P = 0.01).

5. Discussion
Males are highly over-represented in our veterans therefore our results should not be extrapolated to the general
population.

5.1. Methadone-Associated QTc Prolongation

After being on a stable dose of methadone for 8.72 ±
4.50 years there was a statistically significant increase in
the QTc (mean 24 msec). The modification of QTc during
methadone maintenance does not seem to be progressive throughout the years. Our findings are consistent
with those of Wedham and colleagues, who observed an
increase in the QTc from baseline to 4 weeks, 8 weeks and
16 weeks in 23% of patients receiving methadone maintenance treatment with a normal QTc at baseline (12). In
the present study, there was no significant association
between QTc prolongation and the methadone dose similar to the findings of Roy and colleagues who found no
significant correlation between the mean QTc of 420.9 ±
21.2 msec, and the mean daily dose of methadone, which
was 80.4 ± 27.7 mg, in their patients receiving methadone
maintenance treatment (13). In our study however, there
was a significant difference in the methadone dosage between the groups with ≥ 24 msec increase in QTc and <
24 msec increase (88.48 ± 27.20 mg versus 68.96 ± 19.84
mg). But the relationship between methadone dosage,
methadone blood level and QTc prolongation is unclear.
A study by Peles and colleagues found that the dose of
methadone and serum methadone levels did not correlate with QTc (14).

5.2. Age and QTc Prolongation
In general, the aging process is an independent risk
factor for QTc prolongation and for the development of
arrhythmias. The QTc may increase with age secondary
to fibrosis and amyloidosis of the myocardium as well
as cardiac hypertrophy and aortic impedance (15). However, similar to the present work, other studies have produced conflicting results regarding the relationship between age and the QTc. For example, Merri and colleagues
quantified electrographic ventricular repolarization and
found no relationship between age and the QT interval
(16). Due to the narrow age range of our veteran population (56.96 ± 6.48 years), it was highly unlikely that we
would find a significant correlation between age and the
QTc. In addition, we did not explore the impact of other
cardiovascular factors such as smoking status, which
could affect the relationship between age and the QTc.

5.3. Gender and QTc Prolongation

Female gender appears be an independent risk factor
5
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for QTc prolongation. Men exhibit shorter resting QTcs
and are therefore less likely to develop TdP secondary to
the influence of sex hormones on ventricular repolarization (17). A review of FDA databases performed by Ebert
and colleagues found that a higher percentage of women
compared to men developed TdP in response to a variety
of drugs that share an ability to block potassium currents
(18). Due to the low prevalence of females (n = 2) in our
study population, it is highly unlikely that we would find
a statistically significant difference between gender and
the QTc.

5.4. Electrolytes and QTC Prolongation
Fluctuations in electrolytes can prolong the QTc. Hypokalemia, hypomagnesaemia, hypophosphatemia and hypocalcaemia have been associated with increased QTc (1921). The lack of a significant negative correlation between
hypokalemia, hypomagnesaemia or hypophosphatemia
and the QTc observed in our study population can most
likely be attributed to the lack of severe electrolyte abnormalities. Golzari and colleagues examined the effects
of hypokalemia, hypocalcaemia and hypomagnesaemia
on the QTc and observed that the prevalence of abnormal
QTcs varied based on the applied criteria, ranging from
25.2%, when using the most lenient criteria (QTc ≥ 450
msec.), to 3.5%, when the most restrictive criteria were
applied (QTc ≥ 500 msec.) (6). Although the QTc was dichotomized at 450 msec in our study, there was no significant negative correlation found between hypokalemia,
hypomagnesaemia and hypophosphatemia. However,
in our study there was a significant negative association
between calcium and the dichotomized and continuous
QTc. Hypocalcaemia has been shown to prolong the QT
interval and that calcium replacement decreases the QT
interval (22).

5.5. Drug Interactions and QTC Prolongation

Methadone is metabolized hepatically by N-demethylation via various cytochrome P450 isoforms (23).
Therefore, administration of cytochrome P450 inhibitors, such as antidepressants and antipsychotics, will
decrease the metabolism of methadone and enhance its
effects, resulting in QTc prolongation (23). In addition,
independent of cytochrome P450 inhibition, certain SSRIs and antipsychotics can prolong the QTc (24, 25). Selective serotonin reuptake inhibitors (SSRIs), as a class,
are associated with QTc prolongation, with citalopram
being the most likely to be associated with this phenomenon, especially at doses greater than 40 mg/day (23). In
the present study, the lack of a significant correlation
between antidepressants and the QTc can be attributed
to the therapeutic doses of antidepressants used. Additionally, tricyclic anti-depressants (TCA’s) have a higher
rate of QTc prolongation compared to other anti-depressants classes (26). In our study, only 3 of the 24 veterans
on an anti-depressant were being prescribed a TCA. An6

tipsychotics can also prolong the QTc; however, this effect differs based on the particular type of antipsychotic studied (25). Through analysis of 1,017 patients with
schizophrenia, Ozeki and colleagues found that chlorpromazine, intravenous haldol and sultropride were
associated with an increased QTc at therapeutic doses,
whereas olanzapine, quetiapine, risperidone and zotepine were not associated with an increased QTc (25). In
their study, the effect of ziprasidone on the QTc was not
analyzed, which is notable because among the atypical
antipsychotics, ziprasidone appears to be most likely to
prolong the QTc (27). In the present study, the lack of a
significant correlation between antipsychotics and the
QTc can be attributed to the fact that none of the veterans was on chlorpromazine, intravenous haldol, sultropride or ziprasidone.

5.6. Medical Comorbidities and QTc Prolongation
Prolongation of the QTc is observed in a number of
heart conditions, especially in association with structural heart defects such as heart failure (28). The absence
of a significant association between systolic congestive
heart failure and the QTc observed in our veteran population is most likely due to the low prevalence (4.08%)
of veterans with systolic heart failure receiving MMT
and the dynamic nature of the QT interval under heart
failure. Hepatic disease, in particular liver cirrhosis,
has been documented as a risk factor for QTc prolongation (29). QTc prolongation tends to be more severe in
patients with alcoholic cirrhosis or Child-Pugh Class C
cirrhosis (29). The absence of a significant association
between cirrhosis and QTc in our study is due to none of
the veterans having cirrhosis severe enough to be classified as Child-Pugh Class C.
The low incidence (0%) of cardiac arrhythmias observed
in this study could be due to the fact that we were interested in and included only veterans who stayed in the
methadone program for many years, the moderate dose
of methadone prescribed (78.20 ± 25.30 versus 99 ± 49
mg/day) and the relatively low prevalence of electrolyte
abnormalities and medical comorbidities (30). Thus veterans who were originally enrolled in the methadone
maintenance program but left the program in the early
stages of their treatment due to any reason are not included. Therefore including only veterans with long-term
methadone treatment may have excluded those veterans
with more severe QT prolongation or who may have left
the program due to arrhythmias, early on. But epidemiological data do not support a correlation between methadone and substantial TdP mortality (31). We found that after being on methadone for an average of 8.72 ± 4.50 years,
the QTc increased significantly by an average of 24 msec.
The change in the QTc does not appear to be progressive
throughout the years. The higher dose of methadone was
the only clinical risk factor that significantly differentiated those veterans with a QTc change ≥ 24 msec versus
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those veterans with a QTc change < 24 msec. The absence
of a significant correlation observed between the risk factors except calcium and the QTc can be attributed to the
low power of the study (n = 49) as well as the lack of severity and complexity among the assessed co-morbidities.
Thus our data supports that methadone dose is a material factor in QTc increase but does not support the dose
being a risk factor both independently or in combination
with other risk factors for inducing TdP or polymorphic
ventricular arrhythmias (PVA). Concern of increasing arrhythmias in patients on methadone has come mostly
from case-reports, while many epidemiological studies
have not shown a significant increase in arrhythmias (31).
A review by the Cochrane group found no evidence to
support the use of routine EKG monitoring for preventing arrhythmias in methadone maintained patients (32).
The QTc thresholds for ventricular arrhythmias are not
specific and a significant proportion of cardiac events occur at QTc values lower than 450 msec. During long-term
methadone maintenance treatment, there was slight increase in the QTc interval but we did not find evidence of
increased cardiac toxicity as a reason for treatment termination. A limitation of the study is the non-inclusion
of veterans who were originally enrolled in the methadone maintenance program but left the program before
the initiation of the study. Other limitations include the
small cohort size.
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